selective focus close up photo of brown wilson pigskin football on green grass

Algernon Pharmaceuticals has announced that it has appointed Dr. David L Brody as a consultant for its clinical research program for the treatment of traumatic brain injury (TBI) with AP-188 (“N,N-Dimethyltryptamine or DMT”).

Dr Brody is a board-certified neurologist with both a research and clinical specialization in TBI and neurodegenerative diseases. He was the Norman J Stupp Professor of Neurology at the Washington University School of Medicine in St Louis and was also the Washington University site director for the National Football League (NFL) neurological player care program.

His research focuses on accelerating implications for better diagnosis, treatment, and outcomes of traumatic brain injury. Dr. Brody said that he is excited to help further the science and work with Algernon on advancing the DMT research TBI program through clinical trials.

By John Biggs

John Biggs is an entrepreneur, consultant, writer, and maker. He spent fifteen years as an editor for Gizmodo, CrunchGear, and TechCrunch and has a deep background in hardware startups, 3D printing, and blockchain. His work has appeared in Men’s Health, Wired, and the New York Times.

Leave a Reply

Your email address will not be published. Required fields are marked *